Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Marts 2025

Genmab — Marts 2025

Planlagt Fastgjort Låst Flyttet Genmab
961 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #122

    Jeg er da selv ret overbevist om, at Genmabs ekstra fokus på late stage skyldes muligheden for, at de mister deres royalty på CD38 - tænker det da mere som aggressivt end defensivt. Tivdak muligheden opstod fordi Pfizer gerne ville hoppe fra - jeg tror aldrig det bliver et stort produkt, men måske ok som øvelse til der kommer et med pænere potentiale.

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #123

      Hverken Pagano eller Klimovski kan sælge vand i Sahara - de er så tørre og ordentlige, at der aldrig kommer noget nyt fra deres kant.

      1 Reply Last reply
      0
      • L Offline
        L Offline
        lahn1
        wrote on sidst redigeret af
        #124

        Hørte lige CC igen. Der kan jo være en årsag til at han ikke varer på spørgsmålet :-/. Tror også der er late stage fokus grundet optimering af salgs organisationen

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #125

          the enrollment estimate for GEN1286 already raised from 214 to 260 even though only 3 ceters participate (bispecific ADC targeting EGFR and cMET.
          ) https://clinicaltrials.gov/study/NCT06685068?tab=history&a=2&b=3&compareMode=sideBySide#version-content-panel

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #126

            innovaTV 207 Primary Completion brought forward somewhat , maybe we'll see some date towards the end of the year; wondering if any other diseases will be targeted (small chance i guess) https://clinicaltrials.gov/study/NCT03485209?tab=history&a=111&b=112&compareMode=sideBySide#version-content-panel

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #127

              Epcore CLL-1
              expands with 2 arms to include an arm with Epcoritamab + Pirtobrutinib in R/R CLL/SLL. raises enrollment est to 304 from 184. https://clinicaltrials.gov/study/NCT04623541?tab=history&a=25&b=26&compareMode=sideBySide#version-content-panel

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #128

                Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan - amlenetug - https://www.prnewswire.com/news-releases/lundbecks-potential-treatment-for-multiple-system-atrophy-granted-orphan-drug-designation-in-japan-302396851.html

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #129

                  Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 https://ir.genmab.com/news-releases/news-release-details/genmab-announces-johnson-johnson-decision-regarding-hexabodyr

                  1 Reply Last reply
                  0
                  • exitnuE Offline
                    exitnuE Offline
                    exitnu
                    wrote on sidst redigeret af
                    #130

                    Øv ...

                    1 Reply Last reply
                    0
                    • exitnuE Offline
                      exitnuE Offline
                      exitnu
                      wrote on sidst redigeret af
                      #131

                      .. This news does not impact Genmab's 2025 Financial Guidance. ..

                      1 Reply Last reply
                      0
                      • exitnuE Offline
                        exitnuE Offline
                        exitnu
                        wrote on sidst redigeret af
                        #132

                        Fint, så er der klarhed, og nu er det så tid til at kigge fremad 🙂

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #133

                          Det var også kun meget lille forskel til dara.

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #134

                            Som jeg læser det dropper de helt erzo, også i dlbcl og aml?

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #135

                              Ja helt væk - og ja ORR skuffer en del, men synes også dara ligger lidt højt. Lader dog til at det giver dybere responser.

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #136

                                Puha en dyr dag med både Novo Genmab i hegnet

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #137

                                  En ulykke kommer sjældent alene, som min salige mor altid sagde.

                                  1 Reply Last reply
                                  0
                                  • J Offline
                                    J Offline
                                    Journalisten
                                    wrote on sidst redigeret af
                                    #138

                                    Nu bliver det godt nok spændende at se, hvordan kursmålene kommer til at se ud de kommende dage.

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      gentogen
                                      wrote on sidst redigeret af
                                      #139

                                      De vil vel stadig være langt over kursen

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #140

                                        Spændende om det får nogen konsekvenser i ledelsen med alle disse syre fejlskud

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          ProinvestorNEWS
                                          wrote on sidst redigeret af
                                          #141

                                          Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 https://proinvestor.com/investornyt/1289062/genmab-announces-johnson-amp-johnson-decision-regarding-hexabodyreg-cd38

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper